Hims & Hers rises after launching menopause and perimenopause treatments

Hims & Hers ticked up after announcing on Wednesday that it will now offer treatments for perimenopause and menopause, a launch that has been eagerly anticipated by bullish retail investors.

The company said it will offer “personalized menopause and perimenopause treatment plans” that may include prescriptions for pills, patches, or creams. Hims expects to add more treatments to the segment next year, it said.

Last month Hims announced that it would begin offering testosterone treatments. That announcement also included an upcoming partnership with Marius Pharmaceuticals to provide Kyzatrex, a branded and FDA-approved oral testosterone treatment.

The company has focused on growing its offerings now that its ability to sell copies of Novo Nordisk’s blockbuster weight-loss shot became limited earlier this year when the shortage of name-brand doses eased. The company’s last quarterly report missed Wall Street’s revenue estimates and was the first ever sequential decline in its sales.

Hims also announced earlier this month that its chief operating officer, former Amazon executive Nader Kabbani, will step down after less than nine months on the job.